

#3



SEQUENCE LISTING

<110> Gillies, Stephen
Burger, Christa
Lo, Kin-Ming

<120> Enhancing the Circulating Half-Life of Antibody-Based Fusion
Proteins

<130> LEX-011

<140> US 09/780,668

<141> 2001-02-09

<150> US 60/181,768

<151> 2000-02-11

<160> 35

<170> PatentIn version 3.0

<210> 1

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Ig-IL-2 junction sequence

<400> 1

Ser Pro Gly Lys Ala Pro Thr

1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Ig C-terminal sequence

<400> 2

Ser Pro Gly Lys

1

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> human gamma-1 heavy chain gene with a silent mutation

<400> 3
 tccccgggta aa 12

<210> 4
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5' oligonucleotide with a Lys to Ala substitution

<400> 4
 ccgggtgcag cacctacttc aagttctaca aagaaaacac ag 42

<210> 5
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 3' oligonucleotide with a Lys to Ala substitution

<400> 5
 ctgtgttttc tttgtagaac ttgaagtagg tgctgcac 38

<210> 6
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5' oligonucleotide with a Lys to Arg substitution

<400> 6
 ccgggtaggg cgccaacttc aagttctaca aagaaaacac ag 42

<210> 7
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 3' oligonucleotide with a Lys to Arg substitution

<400> 7
 ctgtgttttc tttgtagaac ttgaagttgg cgccctac 38

<210> 8
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> 5' oligonucleotide with a Lys deletion

 <400> 8
 ccgggtgcac ctacttcaag ttctacaaag aaaacacag 39

 <210> 9
 <211> 35
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 3' nucleotide with a Lys deletion

 <400> 9
 ctgtgttttc tttgtagaac ttgaagtagg tgcac 35

 <210> 10
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 5' oligonucleotide with a Lys to Gly substitution

 <400> 10
 ccgggtgggg cccctacttc aagttctaca aagaaaacac ag 42

 <210> 11
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 3' oligonucleotide with a Lys to Gly substitution

 <400> 11
 ctgtgttttc tttgtagaac ttgaagtagg ggccccac 38

 <210> 12
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 5' oligonucleotide with a Lys to Leu substitution

 <400> 12
 ccgggtctgg cgccaacttc aagttctaca aagaaaacac ag 42

 <210> 13
 <211> 38
 <212> DNA

<213> Artificial Sequence

<220>

<223> 3' oligonucleotide with a Lys to Leu substitution

<400> 13

ctgtgttttc tttgtagaac ttgaagttgg cgccagac

38

<210> 14

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> 5' oligonucleotide with a Lys to AlaAlaAla substitution

<400> 14

ccgggtgcag cagctgcccc aacttcaagt tctacaaaga aaacacag

48

<210> 15

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> 3' oligonucleotide with a Lys to AlaAlaAla substitution

<400> 15

ctgtgttttc tttgtagaac ttgaagttgg ggcagctgct gcac

44

<210> 16

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> 5' oligonucleotide with a Lys to Cys substitution

<400> 16

ccgggttgcg caccaacttc aagttctaca aagaaaacac ag

42

<210> 17

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> 3' oligonucleotide with a Lys to Cys substitution

<400> 17

ctgtgttttc tttgtagaac ttgaagttgg tgcgcaac

38

<210> 18
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 5' oligonucleotide with a Lys to Asp substitution

 <400> 18
 ccgggtgacg caccaacttc aagttctaca aagaaaacac ag 42

 <210> 19
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 3' oligonucleotide with a Lys to Asp substitution

 <400> 19
 ctgtgttttc ttgtagaac ttgaagttgg tgcgtcac 38

 <210> 20
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> sequence at the antibody-IL2 gene fusion after linker ligation

 <400> 20
 cccggcatgc gggggtaaa 19

 <210> 21
 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> sequence at antibody-IL2 fusion junction

 <400> 21

 Pro Ala Cys Gly Gly Leu
 1 5

 <210> 22
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> 5' linker sequence

 <400> 22

gggttcagga tccggagg

18

<210> 23
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' linker sequence

<400> 23
cctccggatc ctgaaccc

18

<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence at fusion junction

<400> 24

Pro Gly Ser Gly Ser Gly Gly Gly Lys
1 5

<210> 25
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> 5' oligonucleotide with linker

<400> 25
gggttcaggc tctggatcag ggtccggatc cgg

33

<210> 26
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' oligonucleotide with linker

<400> 26
ccggatccgg accctgatcc agagcctgaa ccc

33

<210> 27
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence at fusion junction after linker insertion

<400> 27

Pro Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Gly Lys
1 5 10

<210> 28
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> 5' oligonucleotide with a Pro to Ala substitution

<400> 28
cgcagaagag cctctccctg tccgc 25

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' oligonucleotide with a Pro to Ala substitution

<400> 29
gcggacaggg agaggctctt ct 22

<210> 30
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> 5' oligonucleotide with a Pro to Leu substitution

<400> 30
cgcagaagag cctctccctg tccct 25

<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' oligonucleotide with a Pro to Leu substitution

<400> 31
agggacaggg agaggctctt ct 22

<210> 32
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> 5' oligonucleotide with a Pro to Gly substitution

<400> 32
cgcagaagag cctctccctg tccgg

25

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> 3' oligonucleotide with a Pro to Gly substitution

<400> 33
ccggacaggg agaggctctt ct

22

<210> 34
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Ig-TNF junction sequence

<400> 34

Ser Pro Gly Lys Val Arg Ser Ser Ser
1 5

<210> 35
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Ig-(deleted Lys)-TNF fusion sequence

<400> 35

Ser Pro Gly Val Arg Ser Ser Ser
1 5